Ubix Therapeutics has signed a licensing agreement with Yuhan Corporation for the global development and commercialization of the prostate cancer treatment candidate UBX-103. 

Yuhan will hold exclusive worldwide rights to develop and commercialize UBX-103 and will lead clinical trial preparations. Ubix will receive an upfront payment of 5 billion KRW and up to 150 billion KRW in milestone payments, plus royalties on future sales.

UBX-103 is based on Ubix's proprietary "Degraducer" platform, designed to degrade androgen receptors (AR), which are overexpressed in prostate cancer. Preclinical studies showed UBX-103's effectiveness in inhibiting tumor growth in castration-resistant prostate cancer models and its ability to degrade AR mutations induced by existing treatments.

Both companies aim to accelerate clinical development and bring UBX-103 to market as a next-generation, best-in-class therapy for hormone-refractory prostate cancer. UBX-103 was also selected for the 2023 National New Drug Development Project, with plans for an IND submission by early 2025.